Oct 2025 $14 M No. 5 $10 to $50 million 1
CoRegen, Inc.: Raise no. 5, Oct 2025 × Investors in this round 1 investor had bought by the notice of Feb 26, 2026: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $14 M of $14 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $540,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Peter W. Gelinas · Executive Officer Sonal Gupta · Executive Officer Sonja Nelson · Executive Officer · Chief Financial Officer and Secretary Steve Gorlin · Executive Officer, Director · President and Vice Chairman of the Board Bert W. O'Malley · Director Edward J. Benz, Jr. · Director Jonathan W. Simons · Director Lee J. Fleisher · Director Suneet J. Varma · Director William J. Haseltine, PhD. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Stonehaven, LLC (CRD 118913) · broker-dealer Terrance Joseph Philips (CRD 8015702) · New York, New York Sold in OH Stonehaven, LLC (CRD 118913) · broker-dealer Marc Christopher Rucinski (CRD 4543011) · New York, New York Sold in OH Signed by Sonja Nelson, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 26, 2026. Read the notice at the SEC .
equity SEC Apr 2025 $63 M No. 4 $50 to $250 million 8
CoRegen, Inc.: Raise no. 4, Apr 2025 × Investors in this round 8 investors had bought by the notice of May 22, 2025: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $63 M of $63 M offered
Smallest investment taken $25,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $4,130,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Clifford C. Dasco, M.D. · Executive Officer, Director · Chief Medical Officer of the Issuer David Lonard, PhD · Executive Officer · Chief Science Officer of the Issuer John Thomas, Jr. · Executive Officer · Chief Financial Officer and Secretary of Issuer Steve Gorlin · Executive Officer, Director · President of the Issuer Bert W. O'Malley · Director Edward J. Benz, Jr. · Director Jonathan W. Simons · Director Lee J. Fleisher, M.D. · Director Suneet J. Varma · Director William J. Haseltine, PhD. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round M M Dillon & Co. LLC (CRD 19878) · broker-dealer Elena Ulansky (CRD 7654267) · Greenwich, Connecticut Sold in FL, NY, TX M M Dillion & Co. LLC (CRD 19878) · broker-dealer Jeff Robert Swarz (CRD 1563420) · Greenwich, Connecticut Sold in FL, NY, TX Remarks in the notice On fees: “Includes 7% warrant coverage issued to Broker where applicable sales commissions were payable”Signed by John C. Thomas Jr., Chief Financial Officer of the Issuer. Source: SEC Form D, newest notice filed May 22, 2025. Read the notice at the SEC .
equity SEC Feb 2025 $10 M No. 3 $10 to $50 million 1
CoRegen, Inc.: Raise no. 3, Feb 2025 × Investors in this round 1 investor had bought by the notice of Feb 28, 2025: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken $25,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $700,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Clifford C. Dasco, M.D. · Executive Officer, Director · Chief Medical Officer of the Issuer David C. Lonard, PhD · Executive Officer · Chief Science Officer of the Issuer John C. Thomas, Jr. · Executive Officer · Chief Financial Officer and Secretary of the Issuer Shawn C. Tomasello · Executive Officer, Director · Chief Executive Officer of the Issuer Bert W. O'Malley · Director Edward J. Benz, Jr. · Director Jonathan W. Simons · Director Lee C. Fleisher, M.D. · Director Steve C. Gorlin · Director William C. Haseltine, PhD. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round M M Dillion & Co. LLC (CRD 19878) · broker-dealer Jeff Robert Swarz (CRD 1563420) · Greenwich, Connecticut Sold in NY M M Dillon & Co. LLC (CRD 19878) · broker-dealer Elena Ulansky (CRD 7654267) · Greenwich, Connecticut Sold in FL Remarks in the notice On fees: “Includes 7% warrant coverage issued to Broker where applicable sales commissions were payable”Signed by John C. Thomas Jr., Chief Financial Officer of the Issuer. Source: SEC Form D, newest notice filed Feb 28, 2025. Read the notice at the SEC .
equity SEC Jan 2025 $21 M No. 2 $10 to $50 million 7
CoRegen, Inc.: Raise no. 2, Jan 2025 × Investors in this round 7 investors had bought by the notice of Feb 28, 2025: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $21 M of $21 M offered
Smallest investment taken $25,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,400,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Clifford C. Dasco, M.D. · Executive Officer, Director · Chief Medical Officer of the Issuer David C. Lonard, PhD · Executive Officer · Chief Science Officer of the Issuer John C. Thomas, Jr. · Executive Officer · Chief Financial Officer and Secretary of the Issuer Shawn C. Tomasello · Executive Officer, Director · Chief Executive Officer of the Issuer Bert W. O'Malley · Director Edward J. Benz, Jr. · Director Jonathan W. Simons · Director Lee C. Fleisher, M.D. · Director Steve C. Gorlin · Director William C. Haseltine, PhD. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round M M Dillion & Co. LLC (CRD 19878) · broker-dealer Jeff Robert Swarz (CRD 1563420) · Greenwich, Connecticut Sold in NY M M Dillon & Co. LLC (CRD 19878) · broker-dealer Elena Ulansky (CRD 7654267) · Greenwich, Connecticut Sold in FL Remarks in the notice On fees: “Includes 7% warrant coverage issued to Broker where applicable sales commissions were payable”Signed by John C. Thomas Jr., Chief Financial Officer of the Issuer. Source: SEC Form D, newest notice filed Feb 28, 2025. Read the notice at the SEC .
equity SEC Feb 2024 $15 M No. 1 $10 to $50 million 1
CoRegen, Inc.: Raise no. 1, Feb 2024 × Investors in this round 1 investor had bought by the notice of Feb 22, 2024: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M (amount offered: indefinite)
Smallest investment taken $14,500,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David C. Lonard, PhD · Executive Officer · Chief Science Officer of the Issuer John C. Thomas, Jr. · Executive Officer · Chief Financial Officer of the Issuer Steve C. Gorlin · Executive Officer, Director · Chief Executive Officer of the Issuer Bert W. O'Malley, M.D. · Director Clifford C. Dasco, M.D. · Director David M. Cornell, II · Director Edward J. Benz, Jr. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John C. Thomas, Jr., Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 22, 2024. Read the notice at the SEC .
equity SEC